Der Markt Für Antivirale Medikamente In Europa: Umfang, Größe Und Wachstum Bis 2030

>Europäischer Markt für antivirale Medikamente nach Indikation (Influenza, Humanes Immundefizienz-Virus (HIV), Hepatitis C-Virus (HCV), Respiratorisches Synzytial-Virus, Herpes-simplex-Virus, Humanes Cytomegalovirus (HCMV), Varizella-Zoster-Virus (VZV), Hepatitis B-Virus (HBV), Coronavirus-Infektion und andere), Patiententyp (Kinder, Erwachsene und geriatrische Patienten), Produkte (oral, topisch und parenteral), Medikamententyp (Generika und Marken), Endverbraucher (Krankenhäuser, Kliniken, häusliche Pflege , Fachzentren, ambulante Zentren und andere), Vertriebskanal (Krankenhausapotheke, Online-Apotheke und Einzelhandelsapotheke) – Branchentrends und Prognose bis 2030.

Marktanalyse und Einblicke für antivirale Medikamente in Europa

Das zunehmende Bewusstsein für Virusinfektionen in Europa hat die Nachfrage auf diesem Markt erhöht. Die steigenden Gesundheitsausgaben für bessere Gesundheitsdienste tragen ebenfalls zum Wachstum des Marktes bei. Die wichtigsten Marktteilnehmer konzentrieren sich in dieser entscheidenden Phase auf die Einführung und Zulassung verschiedener Dienste. Darüber hinaus trägt auch die zunehmende Weiterentwicklung von Techniken zur Arzneimittelentwicklung zur steigenden Nachfrage nach antiviralen Medikamenten bei.

Der europäische Markt für antivirale Medikamente dürfte im Prognosejahr aufgrund der Zunahme der Marktteilnehmer und der Verfügbarkeit fortschrittlicher Dienste wachsen. Darüber hinaus sind die Hersteller in Entwicklungsaktivitäten involviert, um neue Dienste auf den Markt zu bringen. Die zunehmende Entwicklung im Bereich der Arzneimittelentwicklung fördert das Marktwachstum weiter. Schwierigkeiten wie das Fehlen standardisierter Protokolle und der Mangel an qualifizierten Fachkräften könnten jedoch das Wachstum des europäischen Marktes für antivirale Medikamente im Prognosezeitraum behindern.

Steigende Gesundheitsausgaben für Fortschritt und Arzneimittelentwicklung dürften dem Markt Chancen eröffnen. Der zunehmende Einsatz alternativer Behandlungen könnte jedoch das Marktwachstum bremsen. Data Bridge Market Research geht davon aus, dass der europäische Markt für antivirale Medikamente bis 2030 voraussichtlich einen Wert von 22.549,32 Millionen USD erreichen wird, mit einer durchschnittlichen jährlichen Wachstumsrate von 5,3 % während des Prognosezeitraums.

Berichtsmetrik	Details
Prognosezeitraum	2023 bis 2030
Basisjahr	2022
Historische Jahre	2021 (anpassbar auf 2015–2020)
Quantitative Einheiten	Umsatz in Millionen, Mengen in Einheiten und Preise in USD
Abgedeckte Segmente	Indikation (Influenza, Humanes Immundefizienz-Virus (HIV), Hepatitis C-Virus (HCV), Respiratorisches Synzytial-Virus, Herpes-simplex-Virus, Humanes Cytomegalovirus (HCMV), Varizella-Zoster-Virus (VZV), Hepatitis B-Virus (HBV), Coronavirus-Infektion und andere), Patiententyp (Kinder, Erwachsene und geriatrische Patienten), Produkte (oral, topisch und parenteral), Arzneimitteltyp (Generika und Marken), Endverbraucher (Krankenhäuser, Kliniken, häusliche Pflege, Fachzentren, ambulante Zentren und andere), Vertriebskanal (Krankenhausapotheke, Online-Apotheke und Einzelhandelsapotheke)
Abgedeckte Länder	Deutschland, Frankreich, Großbritannien, Ungarn, Litauen, Österreich, Irland, Norwegen, Polen, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei und Rest von Europa
Abgedeckte Marktteilnehmer	Zu den wichtigsten Akteuren auf dem europäischen Markt für antivirale Medikamente zählen unter anderem Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc und Hetero.

Definition des europäischen Marktes für antivirale Medikamente

Antivirale Medikamente sind Medikamente zur Behandlung von Virusinfektionen, indem sie die Replikation von Viren in Wirtszellen hemmen. Diese Medikamente zielen auf bestimmte Viren oder Virentypen ab und wirken, indem sie entweder das Eindringen des Virus in die Wirtszelle verhindern oder wichtige Enzyme oder Proteine blockieren, die für die Virusreplikation erforderlich sind. Im Gegensatz zu Antibiotika, die zur Behandlung bakterieller Infektionen eingesetzt werden, sind antivirale Medikamente im Allgemeinen weniger wirksam, da Viren eine viel einfachere Struktur haben und für ihre Replikation auf Wirtszellen angewiesen sind. Sie können jedoch dennoch bei der Behandlung einiger Virusinfektionen wie Grippe, Herpes und HIV nützlich sein.

Marktdynamik für antivirale Medikamente in Europa

In diesem Abschnitt geht es um das Verständnis der Markttreiber, Chancen, Einschränkungen und Herausforderungen. All dies wird im Folgenden ausführlich erläutert:

Treiber

Steigende Prävalenz von Virusinfektionen

Virusinfektionen haben in den letzten Jahrzehnten weltweit stetig zugenommen. Ein Virus, das in den Körper eindringt, dessen Zellen zur Replikation nutzt und sich ausbreitet, verursacht eine Virusinfektion. Virusinfektionen können verschiedene Symptome hervorrufen, von leichten bis hin zu schweren und in einigen Fällen sogar lebensbedrohlichen. Die Globalisierung ist eine der Hauptursachen für die Zunahme von Virusinfektionen. Menschen reisen und kommunizieren über Grenzen hinweg miteinander, wodurch die Welt vernetzter ist als je zuvor. Die Übertragung von Viren von einem Gebiet zum anderen hat sich aufgrund dieser verstärkten Vernetzung beschleunigt.

Daher ist die zunehmende Verbreitung von Virusinfektionen ein komplexes Problem mit vielen Faktoren. Globalisierung, Bevölkerungsdichte, Klimawandel und Antibiotikaresistenz beeinflussen die Verbreitung von Viren. Daher wird erwartet, dass dies das Marktwachstum ankurbelt.

Fortschritte bei der Entwicklung neuer antiviraler Medikamente

Patienten mit Virusinfektionen werden antivirale Behandlungen verschrieben. Die Entwicklung neuartiger antiviraler Medikamente hat im Laufe der Zeit enorme Fortschritte gemacht. Diese Entwicklungen haben die Krankheitslast verringert, die Behandlung viraler Infektionen verbessert und Leben gerettet. Auf dem Gebiet neuer antiviraler Medikamente gibt es viel Entwicklung.

Fortschritte bei der Entwicklung neuer antiviraler Medikamente haben die Behandlung viraler Infektionen verbessert, die Krankheitslast verringert und dürften das Marktwachstum ankurbeln.

Zurückhaltung

Hohe Kosten für antivirale Medikamente

Die hohen Kosten antiviraler Medikamente können erhebliche Folgen für Patienten und Gesundheitssysteme haben. Patienten, die sich diese Medikamente nicht leisten können, müssen möglicherweise auf eine Behandlung verzichten oder sind auf minderwertige Behandlungen angewiesen, was zu schlechteren Gesundheitsergebnissen führt. Darüber hinaus können die hohen Kosten antiviraler Medikamente die Gesundheitsbudgets belasten, insbesondere in Ländern mit begrenzten Ressourcen.

Daher ist zu erwarten, dass die hohen Kosten antiviraler Medikamente den europäischen Markt für antivirale Medikamente bremsen werden.

Gelegenheit

Neue Wirkstoffverabreichungssysteme

Bei der Forschung zu antiviralen Medikamenten lag der Schwerpunkt auf der Entwicklung neuartiger Verabreichungsmechanismen. Im Vergleich zu herkömmlichen Verabreichungsmethoden bieten neuartige Verabreichungssysteme mehrere Vorteile, wie eine bessere Bioverfügbarkeit, eine maßgeschneiderte Verabreichung der Medikamente und weniger Nebenwirkungen.

Daher ist die Entwicklung neuartiger Arzneimittelverabreichungssysteme ein wichtiger Forschungsbereich für antivirale Medikamente. Arzneimittelverabreichungssysteme mit Nanopartikeln, Hydrogele, Dendrimere, Mikronadeln und zellpenetrierende Peptide sind einige vielversprechende Arzneimittelverabreichungssysteme, die für antivirale Medikamente untersucht wurden. Diese Verabreichungssysteme bieten mehrere Vorteile gegenüber herkömmlichen Arzneimittelverabreichungsmethoden und haben das Potenzial, die Wirksamkeit und Sicherheit antiviraler Medikamente zu verbessern, und dürften eine Chance für das Wachstum des Marktes schaffen.

Herausforderung

Patentablauf bei antiviralen Medikamenten

Der Ablauf eines Patents führt dazu, dass der ursprüngliche Entwickler oder Patentinhaber sein ausschließliches Recht zur Herstellung und Vermarktung eines bestimmten Arzneimittels verliert. Der Ablauf eines Patents für antivirale Medikamente kann erhebliche Auswirkungen auf die Pharmabranche haben, da er möglicherweise Konkurrenz durch Hersteller von Generika nach sich zieht.

Die Patente für antivirale Medikamente erlöschen am Ende der Zeit, in der ihr Hersteller das alleinige Recht hat, das Medikament herzustellen und zu vermarkten. Nach Ablauf des Patents eines Medikaments können andere Hersteller Generika herstellen und vermarkten. Dies kann zu stärkerem Wettbewerb und niedrigeren Verbraucherpreisen führen. HIV, Hepatitis B und C, Herpes, Grippe und andere Viruserkrankungen werden alle mit antiviralen Medikamenten behandelt. Die Patente für antivirale Medikamente erlöschen je nach Medikament und Land zu unterschiedlichen Zeitpunkten. Medikamentenpatente werden normalerweise für 20 Jahre ab dem Anmeldedatum gewährt. Andere Hersteller können nach Ablauf des Patents Generika herstellen und vermarkten. Da der Hersteller nicht so viel für Marketing, Forschung und Entwicklung sowie klinische Studien ausgeben muss, sind Generika oft günstiger als Markenmedikamente.

Der Patentablauf bei antiviralen Medikamenten kann daher erhebliche Auswirkungen auf die Verfügbarkeit, Erschwinglichkeit und Zugänglichkeit dieser wichtigen Medikamente haben und dürfte eine Herausforderung für das Marktwachstum darstellen.

Jüngste Entwicklungen

Im Januar 2023 gab Merck, bekannt als MSD, den erfolgreichen Abschluss des Barübernahmeangebots über eine Tochtergesellschaft für alle ausstehenden Stammaktien von Imago Biosciences, Inc. (Nasdaq: IMGO) zu einem Kaufpreis von 36,00 USD pro Aktie in bar, ohne Zinsen und vorbehaltlich des Abzugs etwaiger erforderlicher Quellensteuern bekannt. Die Übernahme wird zum Umsatzwachstum beitragen.
Im April 2021 gab Zydus Pharmaceuticals, Inc. bekannt, dass es vom Drug Controller General of India (DCGI) eine eingeschränkte Notfallzulassung für das antivirale Medikament Virafin zur Behandlung mittelschwerer COVID-19-Infektionen erhalten habe. Dies wird dem Unternehmen helfen, seine Präsenz in Europa und seinen Ruf in anderen Regionen der Welt zu stärken.

Marktumfang für antivirale Medikamente in Europa

Der europäische Markt für antivirale Medikamente ist in sechs wichtige Segmente unterteilt, basierend auf Indikation, Patiententyp, Produkt, Medikamententyp, Endverbraucher und Vertriebskanal. Das Wachstum zwischen den Segmenten hilft Ihnen, Nischenwachstumsbereiche und Strategien zur Marktbearbeitung zu analysieren und Ihre wichtigsten Anwendungsbereiche und die Unterschiede in Ihren Zielmärkten zu bestimmen.

Anzeige

Grippe
Menschliches Immundefizienz-Virus (HIV)
Hepatitis C-Virus
Herpes Simplex Virus
Humanes Cytomegalievirus (HCMV)
Varizella-Zoster-Virus (VZV)
Hepatitis B Virus
Respiratorisches Synzytial-Virus
Coronavirus Infektion
Sonstiges

Auf der Grundlage der Indikation ist der europäische Markt für antivirale Medikamente in Grippe, menschliches Immundefizienz-Virus (HIV), Hepatitis C-Virus (HCV), Respiratorisches Synzytial-Virus, Herpes-simplex-Virus, menschliches Cytomegalovirus (HCMV), Varizella-Zoster-Virus (VZV), Hepatitis B-Virus (HBV), Coronavirus-Infektion und andere unterteilt.

Patiententyp

Kind
Erwachsene
Geriatrie

Auf der Grundlage des Patiententyps ist der europäische Markt für antivirale Medikamente in Kinder, Erwachsene und geriatrische Patienten segmentiert.

PRODUKTE

Oral
Aktuell
Parenterale

Auf der Grundlage der Produkte ist der europäische Markt für antivirale Medikamente in orale, topische und parenterale Medikamente segmentiert.

Arzneimitteltyp

Generisch
Gebrandmarkt

Auf der Grundlage des Arzneimitteltyps ist der europäische Markt für antivirale Medikamente in Generika und Markenmedikamente unterteilt.

Endbenutzer

Krankenhaus
Kliniken
Häusliche Gesundheitspflege
Spezialzentren
Ambulante Zentren
Sonstiges

Auf der Grundlage des Endverbrauchers ist der europäische Markt für antivirale Medikamente in Krankenhäuser, Kliniken, häusliche Pflege, Fachzentren, ambulante Zentren und andere unterteilt.

Vertriebskanal

Krankenhausapotheke
Online-Apotheke
Einzelhandelsapotheke

Auf der Grundlage der Vertriebskanäle ist der europäische Markt für antivirale Medikamente in Krankenhausapotheken, Online-Apotheken und Einzelhandelsapotheken segmentiert.

Europa: Markt für antivirale Medikamente – regionale Analyse/Einblicke

Der europäische Markt für antivirale Medikamente ist basierend auf Indikation, Patiententyp, Produkt, Medikamententyp, Endverbraucher und Vertriebskanal in sechs wichtige Segmente unterteilt.

Die in diesem Marktbericht abgedeckten Länder sind Deutschland, Frankreich, Großbritannien, Ungarn, Litauen, Österreich, Irland, Norwegen, Polen, Italien, Spanien, Niederlande, Russland, Schweiz, Türkei und das übrige Europa.

Im Jahr 2023 dominiert Deutschland die Region Europa aufgrund der starken Präsenz wichtiger Akteure und aufgrund der steigenden Nachfrage aus den Schwellenmärkten und der Expansion.

Der Länderabschnitt des Berichts enthält auch individuelle marktbeeinflussende Faktoren und Änderungen der Regulierung auf dem Inlandsmarkt, die sich auf die aktuellen und zukünftigen Markttrends auswirken. Datenpunkte wie Neuverkäufe, Ersatzverkäufe, demografische Daten des Landes, Regulierungsgesetze und Import-/Exportzölle sind einige der wichtigsten Anhaltspunkte, die zur Prognose des Marktszenarios für einzelne Länder verwendet werden. Bei der Prognoseanalyse der Länderdaten werden auch die Präsenz und Verfügbarkeit europäischer Marken und ihre Herausforderungen aufgrund großer oder geringer Konkurrenz durch lokale und inländische Marken sowie die Auswirkungen der Vertriebskanäle berücksichtigt.

Wettbewerbsumfeld und Marktanteilsanalyse für antivirale Medikamente in Europa

Die Wettbewerbslandschaft des europäischen Marktes für antivirale Medikamente liefert Details nach Wettbewerbern. Die enthaltenen Details sind Unternehmensübersicht, Unternehmensfinanzen, erzielter Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, Produktionsstandorte und -anlagen, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktzulassungen, Produktbreite und -breite, Anwendungsdominanz und Produkttyp-Lebenslinienkurve. Die oben angegebenen Datenpunkte beziehen sich nur auf den Fokus des Unternehmens auf den europäischen Markt für antivirale Medikamente.

Zu den wichtigsten Akteuren auf dem europäischen Markt für antivirale Medikamente zählen unter anderem Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, Inc., Bristol-Myers Squibb Company, Cipla Inc., Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Zydus Pharmaceuticals, Inc., Mylan Pharmaceuticals ULC, Teva Pharmaceuticals USA, Inc., EMERGENT, Sun Pharmaceutical Industries Ltd., Avet Pharmaceuticals Inc., Pfizer Inc., SIGA Technologies, NAVINTA LLC., Macleods Pharmaceuticals Ltd., BioCryst Pharmaceuticals, Inc. und Hetero.

SKU-70090

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Klicken Sie auf das Bild, um es zu vergrößern

Interaktives Datenanalyse-Dashboard
Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
Zugriff für Research-Analysten für Anpassungen und Abfragen
Konkurrenzanalyse mit interaktivem Dashboard
Aktuelle Nachrichten, Updates und Trendanalyse
Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung

Demo anfordern

Inhaltsverzeichnis

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE EUROPE ANTIVIRAL DRUGS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

5 EPIDEMIOLOGY

6 PIPELINE ANALYSIS FOR EUROPE ANTIVIRAL DRUGS MARKET

7 REGULATORY FRAMEWORK

8 MARKET OVERVIEW

8.1 DRIVERS

8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS

8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT

8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES

8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES

8.2 RESTRAINS

8.2.1 HIGH COST OF ANTIVIRAL DRUGS

8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES

8.3 OPPORTUNITIES

8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS

8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS

8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES

8.4 CHALLENGES

8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS

8.4.2 DEMAND FOR ALTERNATIVE MEDICINES

9 EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION

9.1 OVERVIEW

9.2 INFLUENZA

9.2.1 NEURAMINIDASE INHIBITORS

9.2.1.1 OSELTAMIVIR

9.2.1.2 ZANAMIVIR

9.2.1.3 PERAMIVIR

9.2.1.4 LANINAMIVIR

9.2.2 M2 INHIBITORS

9.2.2.1 RIMANTADINE

9.2.2.2 OTHERS

9.2.3 RNA POLYMERASE INHIBITORS

9.2.3.1 FAVIPIRAVIR

9.2.3.2 BALOXAVIR MARBOXIL

9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV)

9.3.1 REVERSE TRANSCRIPTASE INHIBITORS

9.3.1.1 NUCLEOSIDE (NRTIS)

9.3.1.1.1 LAMIVUDINE

9.3.1.1.2 ABACAVIR

9.3.1.1.3 DIDANOSINE

9.3.1.1.4 OTHERS

9.3.1.2 NONNUCLEOSIDE (NNRTIS)

9.3.1.2.1 EFAVIRENZ

9.3.1.2.2 NEVIRAPINE

9.3.1.2.3 DELAVIRDINE

9.3.1.2.4 OTHERS

9.3.1.3 INTEGRASE

9.3.1.3.1 DOLUTEGRAVIR

9.3.1.3.2 ELVITEGRAVIR

9.3.1.3.3 RALTEGRAVIR

9.3.1.3.4 BICTEGRAVIR

9.3.1.4 NUCLEOTIDE

9.3.1.4.1 TENOFOVIR

9.3.1.4.2 OTHERS

9.3.1.5 INTERFERONS

9.3.1.5.1 ALPHA

9.3.1.5.2 BETA

9.3.1.5.3 GAMMA

9.3.1.6 GP41

9.3.1.6.1 ENFUVIRTIDE

9.3.1.6.2 OTHERS

9.3.2 PROTEASE

9.3.2.1 ATAZANAVIR

9.3.2.2 DARUNAVIR

9.3.2.3 LOPINAVIR

9.3.2.4 RITONAVIR

9.3.2.5 SAQUINAVIR

9.3.2.6 INDINAVIR

9.3.2.7 NELFINAVIR

9.3.2.8 TIPRANAVIR

9.3.2.9 AMPRENAVIR

9.4 HEPATITIS C VIRUS

9.4.1 NS5B POLYMERASE

9.4.1.1 SOFOSBUVIR

9.4.1.2 DASABUVIR

9.4.2 NS3/4A PROTEASE

9.4.2.1 DANOPREVIR

9.4.2.2 GLECAPREVIR

9.4.2.3 GRAZOPREVIR

9.4.2.4 PARITAPREVIR

9.4.2.5 SIMEPREVIR

9.4.3 NS5A PHOSPHOPROTEIN

9.4.3.1 LEDIPASVIR

9.4.3.2 VELPATASVIR

9.4.3.3 OMBITASVIR

9.4.3.4 ELBASVIR

9.4.3.5 DACLATASVIR

9.4.3.6 PIBRENTASVIR

9.4.4 NEURAMINIDASE

9.4.4.1 OSELTAMIVIR

9.4.4.2 ZANAMIVIR

9.4.4.3 PERAMIVIR

9.4.4.4 LANINAMIVIR

9.4.5 RNA POLYMERASE

9.4.5.1 BALOXAVIR MARBOXIL

9.4.5.2 FAVIPIRAVIR

9.4.6 MATRIX PROTEIN 2

9.4.6.1 RIMATIDINE

9.4.6.2 FAVIPIRAVIR

9.5 HERPES SIMPLEX VIRUS

9.5.1 DNA POLYMERASE UL30

9.5.1.1 ACICLOVIR

9.5.1.2 FAMCICLOVIR

9.5.1.3 VALACICLOVIR

9.5.1.4 PENCICLOVIR TRIFLURIDINE

9.5.1.5 BRIVUDINE

9.5.1.6 FOSCARNET

9.5.1.7 IDOXURIDINE

9.5.2 ENVELOPE PROTEINS

9.5.2.1 DOCOSANOL

9.5.2.2 OTHERS

9.6 HUMAN CYTOMEGALOVIRUS (HCMV)

9.6.1 GANCICLOVIR

9.6.2 VALGANCICLOVIR

9.6.3 CIDOFOVIR

9.6.4 FOSCARNET

9.6.5 FOMIVIRSEN

9.7 VARICELLA-ZOSTER VIRUS (VZV)

9.7.1 VALACICLOVIR

9.7.2 FAMCICLOVIR

9.7.3 ACICLOVIR

9.7.4 VIDARABINE

9.7.5 BRIVUDINE

9.8 HEPATITIS B VIRUS

9.8.1 ENTECAVIR

9.8.2 TENOFOVIR

9.8.3 TELBIVUDINE

9.8.4 TENOFOVIR ALAFENAMIDE

9.8.5 OTHERS

9.9 RESPIRATORY SYNCYTIAL VIRUS

9.9.1 RNA POLYMERASE

9.9.1.1 RIBAVIRIN

9.9.1.2 OTHERS

9.9.2 FUSION GLYCOPROTEIN

9.9.2.1 PALIVIZUMAB

9.9.2.2 OTHERS

9.1 CORONAVIRUS INFECTION

9.11 OTHERS

10 EUROPE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE

10.1 OVERVIEW

10.2 GERIATRIC

10.2.1 MALE

10.2.2 FEMALE

10.3 CHILD

10.3.1 MALE

10.3.2 FEMALE

10.4 ADULT

10.4.1 MALE

10.4.2 FEMALE

11 EUROPE ANTIVIRAL DRUGS MARKET, BY PRODUCTS

11.1 OVERVIEW

11.2 ORAL

11.2.1 SOLID

11.2.1.1 TABLETS

11.2.1.2 CAPSULES

11.2.1.3 OTHERS

11.2.2 SEMISOLID

11.2.2.1 GELS

11.2.2.2 EMULSIONS

11.2.2.3 ELIXIRS

11.2.2.4 OTHERS

11.2.3 LIQUID

11.2.3.1 SOLUTIONS

11.2.3.2 SYRUPS

11.2.3.3 OTHERS

11.3 TOPICAL

11.3.1 SEMI-SOLID

11.3.1.1 CREAM

11.3.1.2 OINTMENT

11.3.1.3 GELS

11.3.1.4 OTHERS

11.3.2 LIQUID

11.3.2.1 SOLUTIONS

11.3.2.2 SUSPENSIONS

11.3.3 SOLID

11.3.3.1 POWDERS

11.3.3.2 SUPPOSITORIES

11.3.3.3 ENEMA

11.3.3.4 OTHERS

11.4 PARENTERAL

11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS

11.4.1.1 SOLUTIONS

11.4.1.2 RECONSTITUTED/LYOPHILIZED

11.4.1.3 SUSPENSIONS

11.4.1.4 EMULSIONS

11.4.1.5 OTHERS

11.4.2 NOVEL DRUG DELIVERY FORMULATIONS

11.4.3 COLLOIDAL DISPERSIONS

11.4.4 LONG ACTING INJECTION FORMULATION

12 EUROPE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERIC

12.3 BRANDED

13 EUROPE ANTIVIRAL DRUGS MARKET, BY END USER

13.1 OVERVIEW

13.2 HOSPITAL

13.3 SPECIALTY CENTERS

13.4 AMBULATORY CENTRES

13.5 CLINICS

13.6 HOME HEALTHCARE

13.7 OTHERS

14 EUROPE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 RETAIL PHARMACY

14.4 ONLINE PHARMACY

15 EUROPE ANTIVIRAL DRUGS MARKET, BY REGION

15.1 EUROPE

15.1.1 GERMANY

15.1.2 FRANCE

15.1.3 U.K.

15.1.4 HUNGARY

15.1.5 LITHUANIA

15.1.6 AUSTRIA

15.1.7 IRELAND

15.1.8 NORWAY

15.1.9 POLAND

15.1.10 ITALY

15.1.11 SPAIN

15.1.12 RUSSIA

15.1.13 TURKEY

15.1.14 NETHERLANDS

15.1.15 SWITZERLAND

15.1.16 REST OF EUROPE

16 EUROPE ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: EUROPE

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 GILEAD SCIENCES, INC. (2022)

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENT

18.2 PFIZER INC. (2022)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 SIGA TECHNOLOGIES (2022)

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENT

18.4 GLAXOSMITHKLINE PLC.

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENT

18.5 F. HOFFMANN-LA ROCHE LTD. (2022)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENT

18.6 ABBVIE INC.

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 AUROBINDO PHARMA (2022)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENT

18.8 AVET PHARMACEUTICALS INC.

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENT

18.9 BRISTOLL MYERS SQUIBB (2022)

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENT

18.1 BIOCRYST PHARMACEUTICALS, INC. (2022)

18.10.1 COMPANY SNAPSHOT

18.10.2 REVENUE ANALYSIS

18.10.3 PRODUCT PORTFOLIO

18.10.4 RECENT DEVELOPMENT

18.11 CIPLA INC. (2022)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENT

18.12 DR. REDDY’S LABORATORIES LTD. (2022)

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 EMERGENT (2022)

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENT

18.14 HETERO.

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENT

18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENT

18.16 MACLEODS PHARMACEUTICALS LTD.

18.16.1 COMPANY SNAPSHOT

18.16.2 PRODUCT PORTFOLIO

18.16.3 RECENT DEVELOPMENT

18.17 MERCK & CO., INC, (2022)

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022)

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 NAVINTA LLC.

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022)

18.20.1 COMPANY SNAPSHOT

18.20.2 REVENUE ANALYSIS

18.20.3 PRODUCT PORTFOLIO

18.20.4 RECENT DEVELOPMENT

18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022)

18.21.1 COMPANY SNAPSHOT

18.21.2 REVENUE ANALYSIS

18.21.3 PRODUCT PORTFOLIO

18.21.4 RECENT DEVELOPMENT

18.22 ZYDUS PHARMACEUTICALS, INC. (2022)

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

Tabellenverzeichnis

TABLE 1 EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021- 2030 (USD MILLION)

TABLE 2 EUROPE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 3 EUROPE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 4 EUROPE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 5 EUROPE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 6 EUROPE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 7 EUROPE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 8 EUROPE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 9 EUROPE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 10 EUROPE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 11 EUROPE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 12 EUROPE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 13 EUROPE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 14 EUROPE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 15 EUROPE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 16 EUROPE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 17 EUROPE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 EUROPE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 19 EUROPE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 20 EUROPE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 21 EUROPE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 22 EUROPE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 23 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 24 EUROPE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 25 EUROPE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 EUROPE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 27 EUROPE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 28 EUROPE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 29 EUROPE HUMAN CYTOMEGALOVIRUS (HCMV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 EUROPE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 31 EUROPE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 EUROPE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 33 EUROPE HEPATITIS B VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 EUROPE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 35 EUROPE RESPIRATORY SYNCYTIAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 EUROPE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 37 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 38 EUROPE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 39 EUROPE CORONAVIRUS INFECTION IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 EUROPE OTHERS IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 41 EUROPE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021- 2030 (USD MILLION)

TABLE 42 EUROPE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 EUROPE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 44 EUROPE CHILD IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 45 EUROPE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 46 EUROPE ADULT IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 EUROPE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 48 EUROPE ANTIVIRAL DRUGS MARKET, BY PRODUCT, 2021- 2030 (USD MILLION)

TABLE 49 EUROPE ORAL IN ANTIVIRAL DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 EUROPE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 51 EUROPE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 52 EUROPE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 53 EUROPE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 54 EUROPE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 55 EUROPE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 56 EUROPE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 57 EUROPE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 58 EUROPE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 59 EUROPE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 60 EUROPE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 61 EUROPE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 62 EUROPE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 63 EUROPE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021- 2030 (USD MILLION)

TABLE 64 EUROPE ANTIVIRAL DRUGS MARKET, BY END USER, 2021- 2030 (USD MILLION)

TABLE 65 EUROPE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021- 2030 (USD MILLION)

TABLE 66 EUROPE ANTIVIRAL DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 67 EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 68 EUROPE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 69 EUROPE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 70 EUROPE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 71 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 72 EUROPE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 73 EUROPE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 74 EUROPE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 75 EUROPE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 76 EUROPE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 77 EUROPE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 78 EUROPE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 79 EUROPE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 80 EUROPE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 81 EUROPE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 82 EUROPE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 83 EUROPE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 84 EUROPE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 85 EUROPE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 86 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 87 EUROPE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 88 EUROPE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 89 EUROPE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 90 EUROPE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 91 EUROPE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 92 EUROPE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 93 EUROPE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 94 EUROPE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 95 EUROPE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 96 EUROPE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 97 EUROPE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 98 EUROPE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 99 EUROPE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 100 EUROPE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 101 EUROPE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 102 EUROPE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 103 EUROPE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 104 EUROPE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 105 EUROPE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 106 EUROPE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 107 EUROPE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 108 EUROPE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 109 EUROPE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 110 EUROPE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 111 EUROPE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 112 EUROPE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 113 EUROPE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 114 EUROPE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 115 EUROPE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 116 GERMANY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 117 GERMANY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 118 GERMANY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 119 GERMANY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 120 GERMANY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 121 GERMANY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 122 GERMANY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 123 GERMANY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 124 GERMANY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 125 GERMANY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 126 GERMANY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 127 GERMANY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 128 GERMANY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 129 GERMANY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 130 GERMANY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 131 GERMANY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 132 GERMANY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 133 GERMANY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 134 GERMANY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 135 GERMANY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 136 GERMANY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 137 GERMANY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 138 GERMANY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 139 GERMANY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 140 GERMANY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 141 GERMANY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 142 GERMANY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 143 GERMANY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 144 GERMANY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 145 GERMANY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 146 GERMANY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 147 GERMANY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 148 GERMANY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 149 GERMANY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 150 GERMANY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 151 GERMANY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 152 GERMANY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 153 GERMANY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 154 GERMANY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 155 GERMANY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 156 GERMANY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 157 GERMANY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 158 GERMANY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 159 GERMANY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 160 GERMANY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 161 GERMANY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 162 GERMANY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 163 GERMANY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 164 GERMANY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 165 FRANCE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 166 FRANCE INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 167 FRANCE NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 168 FRANCE M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 169 FRANCE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 170 FRANCE HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 171 FRANCE REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 172 FRANCE NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 173 FRANCE NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 174 FRANCE INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 175 FRANCE NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 176 FRANCE INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 177 FRANCE GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 178 FRANCE PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 179 FRANCE HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 180 FRANCE NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 181 FRANCE NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 182 FRANCE NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 183 FRANCE NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 184 FRANCE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 185 FRANCE MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 186 FRANCE HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 187 FRANCE DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 188 FRANCE ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 189 FRANCE HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 190 FRANCE VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 191 FRANCE DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 192 FRANCE RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 193 FRANCE RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 194 FRANCE FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 195 FRANCE ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 196 FRANCE GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 197 FRANCE CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 198 FRANCE ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 199 FRANCE ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 200 FRANCE ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 201 FRANCE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 202 FRANCE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 203 FRANCE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 204 FRANCE TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 205 FRANCE SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 206 FRANCE LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 207 FRANCE SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 208 FRANCE PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 209 FRANCE CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 210 FRANCE NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 211 FRANCE ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 212 FRANCE ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 213 FRANCE ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 214 U.K. ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 215 U.K. INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 216 U.K. NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 217 U.K. M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 218 U.K. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 219 U.K. HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 220 U.K. REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 221 U.K. NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 222 U.K. NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 223 U.K. INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 224 U.K. NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 225 U.K. INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 226 U.K. GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 227 U.K. PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 228 U.K. HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 229 U.K. NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 230 U.K. NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 231 U.K. NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 232 U.K. NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 233 U.K. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 234 U.K. MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 235 U.K. HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 236 U.K. DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 237 U.K. ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 238 U.K. VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 239 U.K. DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 240 U.K. RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 241 U.K. RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 242 U.K. FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 243 U.K. ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 244 U.K. GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 245 U.K. CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 246 U.K. ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 247 U.K. ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 248 U.K. ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 249 U.K. SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 250 U.K. SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 251 U.K. LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 252 U.K. TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 253 U.K. SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 254 U.K. LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 255 U.K. SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 256 U.K. PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 257 U.K.CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 258 U.K. NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 259 U.K. ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 260 U.K. ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 261 U.K. ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 262 HUNGARY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 263 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 264 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 265 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 266 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 267 HUNGARY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 268 HUNGARY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 269 HUNGARY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 270 HUNGARY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 271 HUNGARY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 272 HUNGARY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 273 HUNGARY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 274 HUNGARY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 275 HUNGARY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 276 HUNGARY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 277 HUNGARY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 278 HUNGARY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 279 HUNGARY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 280 HUNGARY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 281 HUNGARY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 282 HUNGARY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 283 HUNGARY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 284 HUNGARY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 285 HUNGARY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 286 HUNGARY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 287 HUNGARY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 288 HUNGARY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 289 HUNGARY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 290 HUNGARY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 291 HUNGARY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 292 HUNGARY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 293 HUNGARY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 294 HUNGARY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 295 HUNGARY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 296 HUNGARY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 297 HUNGARY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 298 HUNGARY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 299 HUNGARY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 300 HUNGARY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 301 HUNGARY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 302 HUNGARY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 303 HUNGARY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 304 HUNGARY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 305 HUNGARY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 306 HUNGARY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 307 HUNGARY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 308 HUNGARY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 309 HUNGARY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 310 HUNGARY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 311 HUNGARY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 312 HUNGARY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 313 LITHUANIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 314 LITHUANIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 315 LITHUANIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 316 LITHUANIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 317 LITHUANIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 318 LITHUANIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 319 LITHUANIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 320 LITHUANIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 321 LITHUANIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 322 LITHUANIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 323 LITHUANIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 324 LITHUANIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 325 LITHUANIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 326 LITHUANIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 327 LITHUANIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 328 LITHUANIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 329 LITHUANIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 330 LITHUANIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 331 LITHUANIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 332 LITHUANIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 333 LITHUANIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 334 LITHUANIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 335 LITHUANIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 336 LITHUANIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 337 LITHUANIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 338 LITHUANIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 339 LITHUANIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 340 LITHUANIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 341 LITHUANIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 342 LITHUANIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 343 LITHUANIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 344 LITHUANIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 345 LITHUANIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 346 LITHUANIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 347 LITHUANIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 348 LITHUANIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 349 LITHUANIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 350 LITHUANIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 351 LITHUANIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 352 LITHUANIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 353 LITHUANIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 354 LITHUANIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 355 LITHUANIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 356 LITHUANIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 357 LITHUANIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 358 LITHUANIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 359 LITHUANIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 360 LITHUANIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 361 LITHUANIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 362 AUSTRIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 363 AUSTRIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 364 AUSTRIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 365 AUSTRIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 366 AUSTRIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 367 AUSTRIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 368 AUSTRIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 369 AUSTRIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 370 AUSTRIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 371 AUSTRIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 372 AUSTRIA NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 373 AUSTRIA INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 374 AUSTRIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 375 AUSTRIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 376 AUSTRIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 377 AUSTRIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 378 AUSTRIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 379 AUSTRIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 380 AUSTRIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 381 AUSTRIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 382 AUSTRIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 383 AUSTRIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 384 AUSTRIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 385 AUSTRIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 386 AUSTRIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 387 AUSTRIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 388 AUSTRIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 389 AUSTRIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 390 AUSTRIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 391 AUSTRIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 392 AUSTRIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 393 AUSTRIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 394 AUSTRIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 395 AUSTRIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 396 AUSTRIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 397 AUSTRIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 398 AUSTRIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 399 AUSTRIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 400 AUSTRIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 401 AUSTRIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 402 AUSTRIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 403 AUSTRIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 404 AUSTRIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 405 AUSTRIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 406 AUSTRIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 407 AUSTRIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 408 AUSTRIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 409 AUSTRIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 410 AUSTRIA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 411 IRELAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 412 IRELAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 413 IRELAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 414 IRELAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 415 IRELAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 416 IRELAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 417 IRELAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 418 IRELAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 419 IRELAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 420 IRELAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 421 IRELAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 422 IRELAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 423 IRELAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 424 IRELAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 425 IRELAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 426 IRELAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 427 IRELAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 428 IRELAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 429 IRELAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 430 IRELAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 431 IRELAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 432 IRELAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 433 IRELAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 434 IRELAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 435 IRELAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 436 IRELAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 437 IRELAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 438 IRELAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 439 IRELAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 440 IRELAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 441 IRELAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 442 IRELAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 443 IRELAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 444 IRELAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 445 IRELAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 446 IRELAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 447 IRELAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 448 IRELAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 449 IRELAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 450 IRELAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 451 IRELAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 452 IRELAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 453 IRELAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 454 IRELAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 455 IRELAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 456 IRELAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 457 IRELAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 458 IRELAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 459 IRELAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 460 NORWAY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 461 NORWAY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 462 NORWAY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 463 NORWAY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 464 NORWAY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 465 NORWAY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 466 NORWAY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 467 NORWAY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 468 NORWAY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 469 NORWAY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 470 NORWAY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 471 NORWAY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 472 NORWAY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 473 NORWAY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 474 NORWAY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 475 NORWAY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 476 NORWAY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 477 NORWAY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 478 NORWAY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 479 NORWAY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 480 NORWAY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 481 NORWAY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 482 NORWAY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 483 NORWAY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 484 NORWAY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 485 NORWAY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 486 NORWAY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 487 NORWAY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 488 NORWAY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 489 NORWAY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 490 NORWAY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 491 NORWAY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 492 NORWAY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 493 NORWAY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 494 NORWAY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 495 NORWAY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 496 NORWAY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 497 NORWAY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 498 NORWAY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 499 NORWAY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 500 NORWAY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 501 NORWAY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 502 NORWAY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 503 NORWAY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 504 NORWAY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 505 NORWAY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 506 NORWAY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 507 NORWAY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 508 NORWAY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 509 POLAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 510 POLAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 511 POLAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 512 POLAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 513 POLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 514 POLAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 515 POLAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 516 POLAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 517 POLAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 518 POLAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 519 POLAND NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 520 POLAND INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 521 POLAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 522 POLAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 523 POLAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 524 POLAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 525 POLAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 526 POLAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 527 POLAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 528 POLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 529 POLAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 530 POLAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 531 POLAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 532 POLAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 533 POLAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 534 POLAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 535 POLAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 536 POLAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 537 POLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 538 POLAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 539 POLAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 540 POLAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 541 POLAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 542 POLAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 543 POLAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 544 POLAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 545 POLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 546 POLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 547 POLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 548 POLAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 549 POLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 550 POLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 551 POLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 552 POLAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 553 POLAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 554 POLAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 555 POLAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 556 POLAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 557 POLAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 558 ITALY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 559 ITALY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 560 ITALY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 561 ITALY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 562 ITALY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 563 ITALY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 564 ITALY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 565 ITALY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 566 ITALY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 567 ITALY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 568 ITALY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 569 ITALY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 570 ITALY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 571 ITALY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 572 ITALY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 573 ITALY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 574 ITALY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 575 ITALY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 576 ITALY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 577 ITALY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 578 ITALY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 579 ITALY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 580 ITALY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 581 ITALY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 582 ITALY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 583 ITALY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 584 ITALY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 585 ITALY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 586 ITALY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 587 ITALY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 588 ITALY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 589 ITALY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 590 ITALY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 591 ITALY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 592 ITALY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 593 ITALY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 594 ITALY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 595 ITALY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 596 ITALY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 597 ITALY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 598 ITALY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 599 ITALY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 600 ITALY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 601 ITALY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 602 ITALY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 603 ITALY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 604 ITALY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 605 ITALY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 606 ITALY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 607 SPAIN ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 608 SPAIN INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 609 SPAIN NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 610 SPAIN M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 611 SPAIN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 612 SPAIN HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 613 SPAIN REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 614 SPAIN NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 615 SPAIN NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 616 SPAIN INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 617 SPAIN NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 618 SPAIN INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 619 SPAIN GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 620 SPAIN PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 621 SPAIN HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 622 SPAIN NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 623 SPAIN NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 624 SPAIN NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 625 SPAIN NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 626 SPAIN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 627 SPAIN MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 628 SPAIN HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 629 SPAIN DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 630 SPAIN ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 631 SPAIN HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 632 SPAIN VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 633 SPAIN DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 634 SPAIN RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 635 SPAIN RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 636 SPAIN FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 637 SPAIN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 638 SPAIN GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 639 SPAIN CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 640 SPAIN ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 641 SPAIN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 642 SPAIN ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 643 SPAIN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 644 SPAIN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 645 SPAIN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 646 SPAIN TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 647 SPAIN SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 648 SPAIN LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 649 SPAIN SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 650 SPAIN PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 651 SPAIN CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 652 SPAIN NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 653 SPAIN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 654 SPAIN ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 655 SPAIN ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 656 RUSSIA ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 657 RUSSIA INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 658 RUSSIA NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 659 RUSSIA M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 660 RUSSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 661 RUSSIA HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 662 RUSSIA REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 663 RUSSIA NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 664 RUSSIA NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 665 RUSSIA INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 666 RUSSIA GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 667 RUSSIA PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 668 RUSSIA HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 669 RUSSIA NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 670 RUSSIA NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 671 RUSSIA NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 672 RUSSIA NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 673 RUSSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 674 RUSSIA MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 675 RUSSIA HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 676 RUSSIA DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 677 RUSSIA ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 678 RUSSIA HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 679 RUSSIA VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 680 RUSSIA DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 681 RUSSIA RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 682 RUSSIA RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 683 RUSSIA FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 684 RUSSIA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 685 RUSSIA GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 686 RUSSIA CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 687 RUSSIA ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 688 RUSSIA ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 689 RUSSIA ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 690 RUSSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 691 RUSSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 692 RUSSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 693 RUSSIA TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 694 RUSSIA SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 695 RUSSIA LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 696 RUSSIA SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 697 RUSSIA PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 698 RUSSIA CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 699 RUSSIA NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 700 RUSSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 701 RUSSIA ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 702 RUSSIA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 703 TURKEY ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 704 TURKEY INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 705 TURKEY NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 706 TURKEY M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 707 TURKEY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 708 TURKEY HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 709 TURKEY REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 710 TURKEY NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 711 TURKEY NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 712 TURKEY INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 713 TURKEY NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 714 TURKEY INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 715 TURKEY GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 716 TURKEY PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 717 TURKEY HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 718 TURKEY NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 719 TURKEY NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 720 TURKEY NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 721 TURKEY NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 722 TURKEY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 723 TURKEY MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 724 TURKEY HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 725 TURKEY DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 726 TURKEY ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 727 TURKEY HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 728 TURKEY VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 729 TURKEY DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 730 TURKEY RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 731 TURKEY RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 732 TURKEY FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 733 TURKEY ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 734 TURKEY GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 735 TURKEY CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 736 TURKEY ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 737 TURKEY ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 738 TURKEY ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 739 TURKEY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 740 TURKEY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 741 TURKEY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 742 TURKEY TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 743 TURKEY SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 744 TURKEY LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 745 TURKEY SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 746 TURKEY PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 747 TURKEY CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 748 TURKEY NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 749 TURKEY ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 750 TURKEY ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 751 TURKEY ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 752 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 753 NETHERLANDS INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 754 NETHERLANDS NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 755 NETHERLANDS M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 756 NETHERLANDS RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 757 NETHERLANDS HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 758 NETHERLANDS REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 759 NETHERLANDS NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 760 NETHERLANDS NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 761 NETHERLANDS INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 762 NETHERLANDS NUCLEOTIDE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 763 NETHERLANDS INTERFERONS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 764 NETHERLANDS GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 765 NETHERLANDS PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 766 NETHERLANDS HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 767 NETHERLANDS NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 768 NETHERLANDS NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 769 NETHERLANDS NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 770 NETHERLANDS NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 771 NETHERLANDS RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 772 NETHERLANDS MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 773 NETHERLANDS HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 774 NETHERLANDS ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 775 NETHERLANDS HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 776 NETHERLANDS VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 777 NETHERLANDS DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 778 NETHERLANDS RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 779 NETHERLANDS RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 780 NETHERLANDS FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 781 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 782 NETHERLANDS GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 783 NETHERLANDS CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 784 NETHERLANDS ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 785 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 786 NETHERLANDS ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 787 NETHERLANDS SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 788 NETHERLANDS SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 789 NETHERLANDS LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 790 NETHERLANDS TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 791 NETHERLANDS SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 792 NETHERLANDS LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 793 NETHERLANDS SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 794 NETHERLANDS PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 795 NETHERLANDS CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 796 NETHERLANDS NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 797 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 798 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 799 NETHERLANDS ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 800 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 801 SWITZERLAND INFLUENZA IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 802 SWITZERLAND NEURAMINIDASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 803 SWITZERLAND M2 INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 804 SWITZERLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 805 SWITZERLAND HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 806 SWITZERLAND REVERSE TRANSCRIPTASE INHIBITORS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 807 SWITZERLAND NUCLEOSIDE (NRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 808 SWITZERLAND NONNUCLEOSIDE (NNRTIS) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 809 SWITZERLAND INTEGRASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 810 SWITZERLAND GP41 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 811 SWITZERLAND PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 812 SWITZERLAND HEPATITIS C VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 813 SWITZERLAND NS5B POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 814 SWITZERLAND NS3/4A PROTEASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 815 SWITZERLAND NS5A PHOSPHOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 816 SWITZERLAND NEURAMINIDASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 817 SWITZERLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 818 SWITZERLAND MATRIX PROTEIN 2 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 819 SWITZERLAND HERPES SIMPLEX VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 820 SWITZERLAND DNA POLYMERASE UL30 IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 821 SWITZERLAND ENVELOPE PROTEINS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 822 SWITZERLAND HUMAN CYTOMEGALOVIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 823 SWITZERLAND VARICELLA-ZOSTER VIRUS (VZV) IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 824 SWITZERLAND DNA POLYMERASE ADEFOVIR IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 825 SWITZERLAND RESPIRATORY SYNCYTICAL VIRUS IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 826 SWITZERLAND RNA POLYMERASE IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 827 SWITZERLAND FUSION GLYCOPROTEIN IN ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 828 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 829 SWITZERLAND GERIATRIC IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 830 SWITZERLAND CHILD IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 831 SWITZERLAND ADULT IN ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 832 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 833 SWITZERLAND ORAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 834 SWITZERLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 835 SWITZERLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 836 SWITZERLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 837 SWITZERLAND TOPICAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 838 SWITZERLAND SEMI-SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 839 SWITZERLAND LIQUID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 840 SWITZERLAND SOLID IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 841 SWITZERLAND PARENTERAL IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 842 SWITZERLAND CONVENTIONAL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 843 SWITZERLAND NOVEL DRUG DELIVERY FORMULATIONS IN ANTIVIRAL DRUGS MARKET, BY PRODUCTS, 2021-2030 (USD MILLION)

TABLE 844 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 845 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 846 SWITZERLAND ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 847 REST OF EUROPE ANTIVIRAL DRUGS MARKET, BY INDICATION, 2021-2030 (USD MILLION)

Abbildungsverzeichnis

FIGURE 1 EUROPE ANTIVIRAL DRUGS: SEGMENTATION

FIGURE 2 EUROPE ANTIVIRAL DRUGS MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE ANTIVIRAL DRUGS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE ANTIVIRAL DRUGS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE ANTIVIRAL DRUGS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE ANTIVIRAL DRUGS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE ANTIVIRAL DRUGS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE ANTIVIRAL DRUGS MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 EUROPE ANTIVIRAL DRUGS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE ANTIVIRAL DRUGS MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF VIRAL INFECTIONS IS EXPECTED TO DRIVE THE EUROPE ANTIVIRAL DRUGS MARKET IN THE FORECAST PERIOD

FIGURE 12 THE INFLUENZA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE ANTIVIRAL DRUGS MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE ANTIVIRAL DRUGS MARKET

FIGURE 14 EUROPE ANTIVIRAL DRUGS MARKET: BY INDICATION , 2022

FIGURE 15 EUROPE ANTIVIRAL DRUGS MARKET: BY INDICATION , 2023-2030 (USD MILLION)

FIGURE 16 EUROPE ANTIVIRAL DRUGS MARKET: BY INDICATION , CAGR (2023-2030)

FIGURE 17 EUROPE ANTIVIRAL DRUGS MARKET: BY INDICATION , LIFELINE CURVE

FIGURE 18 EUROPE ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2022

FIGURE 19 EUROPE ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)

FIGURE 20 EUROPE ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, CAGR (2023-2030)

FIGURE 21 EUROPE ANTIVIRAL DRUGS MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 22 EUROPE ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2022

FIGURE 23 EUROPE ANTIVIRAL DRUGS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 24 EUROPE ANTIVIRAL DRUGS MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 25 EUROPE ANTIVIRAL DRUGS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 26 EUROPE ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2022

FIGURE 27 EUROPE ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)

FIGURE 28 EUROPE ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 29 EUROPE ANTIVIRAL DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 30 EUROPE ANTIVIRAL DRUGS MARKET: BY END USER, 2022

FIGURE 31 EUROPE ANTIVIRAL DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 32 EUROPE ANTIVIRAL DRUGS MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 EUROPE ANTIVIRAL DRUGS MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 EUROPE ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 EUROPE ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 36 EUROPE ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 EUROPE ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 EUROPE ANTIVIRAL DRUGS MARKET: SNAPSHOT (2022)

FIGURE 39 EUROPE ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022)

FIGURE 40 EUROPE ANTIVIRAL DRUGS MARKET: BY COUNTRY (2023 & 2030)

FIGURE 41 EUROPE ANTIVIRAL DRUGS MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 EUROPE ANTIVIRAL DRUGS MARKET: INDICATION (2023-2030)

FIGURE 43 EUROPE ANTIVIRAL DRUGS MARKET: COMPANY SHARE 2022 (%)

Detaillierte Informationen anzeigen

Forschungsmethodik

Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.

Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.

Anpassung möglich

Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.

Häufig gestellte Fragen

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The Europe Antiviral Drugs Market is projected to grow at a CAGR of 5.3% during the forecast period by 2030.

What will be the market value in the future?

The future market value of the Europe Antiviral Drugs Market is expected to reach USD 22,549.32 million by 2030.

Who are the major players operating in the market?

The major players in the Europe Antiviral Drugs Market are Some of the key players operating in the Europe antiviral drugs market are Gilead Sciences, Inc., F. Hoffmann-La Roche Ltd, GLAXOSMITHKLINE PLC, Abbvie, Merck & Co., Inc., Johnson & Johnson Services, etc.

Which countries data are covered in the report?

The countries covered in the Europe Antiviral Drugs Market are Germany, France, U.K, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, and Rest of Europe.

Europäischer Markt für antivirale Medikamente – Branchentrends und Prognose bis 2030

Europäischer Markt für antivirale Medikamente – Branchentrends und Prognose bis 2030

Marktanalyse und Einblicke für antivirale Medikamente in Europa

Definition des europäischen Marktes für antivirale Medikamente

Marktdynamik für antivirale Medikamente in Europa

Marktumfang für antivirale Medikamente in Europa

Europa: Markt für antivirale Medikamente – regionale Analyse/Einblicke

Wettbewerbsumfeld und Marktanteilsanalyse für antivirale Medikamente in Europa

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Berichte

Markteinblicke

Unterstützung

Lösungen

Europäischer Markt für antivirale Medikamente – Branchentrends und Prognose bis 2030

Europäischer Markt für antivirale Medikamente – Branchentrends und Prognose bis 2030

Marktanalyse und Einblicke für antivirale Medikamente in Europa

Definition des europäischen Marktes für antivirale Medikamente

Marktdynamik für antivirale Medikamente in Europa

Marktumfang für antivirale Medikamente in Europa

Europa: Markt für antivirale Medikamente – regionale Analyse/Einblicke

Wettbewerbsumfeld und Marktanteilsanalyse für antivirale Medikamente in Europa

Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud

Inhaltsverzeichnis

Tabellenverzeichnis

Abbildungsverzeichnis

Forschungsmethodik

Anpassung möglich

Häufig gestellte Fragen

Verwandte Seiten durchsuchen